Tideglusib for Arrhythmogenic Cardiomyopathy
(TaRGET Trial)
Recruiting at 20 trial locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Recruiting
Sponsor: Hamilton Health Sciences Corporation
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
Research Team
JD
Jason D Roberts, MD MAS
Principal Investigator
McMaster University and Population Health Research Institute
Eligibility Criteria
This trial is for individuals with a genetic form of arrhythmogenic cardiomyopathy, which affects the heart muscle and can cause irregular heartbeats. Participants must meet specific criteria that will be detailed by the study organizers.Inclusion Criteria
I have been diagnosed with ACM or known as a genetic carrier for at least 6 months.
I have a specific genetic mutation linked to heart disease.
Mean ≥ 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor
Exclusion Criteria
Patients unwilling to provide informed consent or comply with follow-up
Hypersensitivity to tideglusib or any components of its formulation, including allergy to strawberry
I have heart scar tissue from blocked heart arteries.
See 10 more
Treatment Details
Interventions
- Tideglusib (Glycogen Synthase Kinase-3 Inhibitor)
Trial OverviewThe TaRGET study tests tideglusib, a drug aimed at inhibiting an enzyme involved in this type of heart disease, against a placebo. It's randomized and double-blind, meaning neither participants nor researchers know who gets the real drug or placebo.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: TideglusibActive Control1 Intervention
Randomization to Tideglusib 1g po daily or matching placebo
Group II: PlaceboPlacebo Group1 Intervention
Randomization to matching placebo 1g po daily
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hamilton Health Sciences Corporation
Lead Sponsor
Trials
380
Recruited
345,000+
Hearts in Rhythm Organization (HiRO)
Collaborator
Trials
1
Recruited
120+
Population Health Research Institute
Collaborator
Trials
165
Recruited
717,000+
AMO Pharma
Collaborator
Trials
1
Recruited
120+
Canadian Institutes of Health Research (CIHR)
Collaborator
Trials
1,417
Recruited
26,550,000+
Canadian SADS
Collaborator
Trials
1
Recruited
120+